VAXIL BIO LTD. announced that Dr. Yuval Avnir, PhD a translational scientist with expertise in the fields of immunology, infectious diseases, and cancer has been appointed as the company's interim chief executive officer while the company's board of directors continues to search for a CEO, as a result of David Goren’s previously announced resignation. Dr. Avnir has been the company's head of research and development since September 2020. The company further updates that Mr. Gadi Levin, a director and current CFO of the Company will replace Mr. Goren as Chairman of the Board. Dr. Yuval Avnir is a translational scientist with expertise in the fields of immunology, infectious diseases, and cancer who has successfully led numerous novel immunological therapeutic scientific projects. He is an author of peer reviewed scientific papers and co-inventor of patents that encompass diverse scientific fields and detail his broad technical expertise. Mr. Goren will continue to serve as a director on the Board. In addition, Vaxil is continuing to progress the licensed P-Esbp polymer invented by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev. P-Esbp is a drug carrying polymer that targets with high affinity The cell adhesion molecule E-selectin, which is an important component in metastasis and tumor growth processes. Prof. Ayelet’s previous work demonstrated therapeutic efficacy of P-Esbp in animal models for cancer, and Vaxil together with Prof. Ayelet’s laboratory, are continuing to explore the therapeutic efficacy of P-Esbp in other types of cancer as part of the decision process for the clinical program.